United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors

SILVER SPRING, Md: United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell, M.D. to its Board of Directors as an independent director, effective as of September 10, 2020.

Dr. Maxwell has been a head and neck surgeon since 2006, and is a medical educator, a published scientific author, and a health technology entrepreneur and innovator.

Dr. Maxwell is Adjunct Professor of Surgery at the University of Toronto, Distinguished Visiting Professor at Ryerson University, and Associate Scientist at the Li Ka Shing Knowledge Institute in Toronto. She served as Founding and Executive Director of the Biomedical Zone in 2015 – Canada’s first and only hospital-embedded, physician-led business incubator for emerging health technology companies – and has guided a wide variety of startup companies through clinical development, capitalization, and commercialization. Dr. Maxwell also managed a life sciences tech transfer portfolio at the University of Oxford and the UK National Health Service, executing patent strategy, spin-out company formation, and early stage capital raising. She has also served as a healthcare innovation expert to various Canadian federal, provincial, and local government entities, as a member of the Department Audit Committee of the Public Health Agency of Canada, and as an advisor to the Canadian Medical Association and the Canadian Space Agency.

Dr. Maxwell earned an A.B. with honors from Harvard University, an M.D. from Yale University, and an M.B.A. from the University of Oxford. She serves as an independent member of the Board of Directors of Profound Medical Inc., a publicly-traded company listed both in the United States and Canada.

“We greatly value Dr. Maxwell’s outstanding achievements and experience,” said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. “Her knowledge and business expertise position her well to serve on our Board of Directors.”

“I am thrilled to join the United Therapeutics family as an independent director,” said Dr. Maxwell. “It is a privilege to join an extraordinary organization tackling some of the most pernicious problems in medicine through scientific ingenuity, visionary leadership, and a singular commitment to advancing human health.”